



**HAL**  
open science

## **Crystalline silica exposure in patients with rheumatoid arthritis and systemic sclerosis: a nationwide cross-sectional survey**

Catherine Cavalin, Alain Lescoat, Johanna Sigaux, Odile Macchi, Alice Ballerie, Mickaël Catinon, Michel Vincent, Luca Semerano, Marie-Christophe Boissier, Paul-André Rosental

### ► **To cite this version:**

Catherine Cavalin, Alain Lescoat, Johanna Sigaux, Odile Macchi, Alice Ballerie, et al.. Crystalline silica exposure in patients with rheumatoid arthritis and systemic sclerosis: a nationwide cross-sectional survey. *Rheumatology*, 2022, 62 (8), pp.2707-2715. 10.1093/rheumatology/keac675 . hal-03896570

**HAL Id: hal-03896570**

**<https://hal.inrae.fr/hal-03896570>**

Submitted on 13 Dec 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title page**

2

3 ***TITLE of the article***

4 *Occupational exposure to crystalline silica in patients with systemic sclerosis and rheumatoid arthritis. Findings from*  
5 *a thorough questionnaire in a nationwide cross-sectional study*

6

7 Catherine Cavalin<sup>1,2,3a§</sup>, Alain Lescoat<sup>4,5a</sup>, Johanna Sigaux<sup>6,7a</sup>, Odile Macchi<sup>8,9</sup>, Alice Ballerie<sup>4,5</sup>,  
8 Mickaël Catinon<sup>10</sup>, Michel Vincent<sup>10</sup>, Luca Semerano<sup>7,11b</sup>, Marie-Christophe Boissier<sup>7,11b</sup>, Paul-  
9 André Rosental<sup>12b</sup>

10 <sup>a</sup>: equal contribution

11 <sup>b</sup>: equal contribution

12

13 <sup>§</sup>: Catherine Cavalin is the corresponding author / Institution of affiliation: IRISSO, UMR  
14 CNRS-INRAE 7170-1427, Paris-Dauphine University, PSL, Place du Maréchal de Lattre de  
15 Tassigny, 75775 Paris Cedex 16, France / email address: [catherine.cavalin@dauphine.psl.eu](mailto:catherine.cavalin@dauphine.psl.eu)

16

17 1 – IRISSO, UMR CNRS-INRAE 7170-1427, Paris-Dauphine University, PSL, Place du Maréchal de Lattre de  
18 Tassigny, 75775 Paris Cedex 16, France

19 2 – Laboratory for Interdisciplinary Evaluation of Public Policies (LIEPP), Sciences Po, 27, rue Saint-Guillaume, 75337  
20 Paris Cedex 07, France

21 3 – Centre d'études de l'emploi et du travail (CEET, CNAM), 29 Promenade Michel Simon, 93160 Noisy-le-Grand,  
22 France

23 4 – Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, 2 Rue Henri le Guilloux,  
24 35000 Rennes, France

25 5 – Inserm, EHESP, Irset (Institute for Research in Health, Environment and Work) – UMR\_S 1085, Rue du Thabor,  
26 France

27 6 – Inserm U1125, Sorbonne Paris Nord University, Li2P, 9 Rue de Chablis, 93000 Bobigny, France

28 7 – Assistance Publique-Hôpitaux de Paris, GH HUPSSD, Rheumatology Department, 125 rue de Stalingrad, Bobigny,  
29 France

30 8 – Investigation Department of the International Observatory of Prisons (OIP), Paris, France

31 9 – Centre for the Study of Social Movements (CEMS), École des Hautes Études en Sciences Sociales (EHESS), Paris,  
32 France

33 10 – MINAPATH Développement, 56 Boulevard Niels Bohr, CEI2, CS: 52132  
34 69603 Villeurbanne Cedex, France

35 11 – Assistance Publique-Hôpitaux de Paris, GH HUPSSD, Respiratory Department, 125 rue de Stalingrad, Bobigny,  
36 France, INSERM 1272, Université Sorbonne Paris Nord, 9 Rue de Chablis, 93000 Bobigny, France

37 12 – Centre for History, Sciences Po (CHSP), 27, rue Saint-Guillaume, 75337 Paris Cedex 07, France

38

39 All authors meet the following four ICMJE criteria:

- 40 - Substantial contributions to the conception or design of the work; or the acquisition,  
41 analysis, or interpretation of data for the work; AND
- 42 - Drafting the work or revising it critically for important intellectual content; AND
- 43 - Final approval of the version to be published; AND
- 44 - Agreement to be accountable for all aspects of the work in ensuring that questions related  
45 to the accuracy or integrity of any part of the work are appropriately investigated and  
46 resolved.

47

48 **Funding:** SILICOSIS Project, led by Paul-André Rosental, Centre for European Studies and  
49 Comparative Politics, Sciences Po (Paris, France), sponsored by the European Research Council  
50 (ERC); (grant number ERC-2011-ADG\_20110406, project ID 295817)

51

52 **Data availability statement:** The data that support the findings of this study are available upon  
53 reasonable request to the corresponding author.

54

55

56

57 **Abstract** (250 words, divided into Objectives, Methods, Results and Conclusion): **242 words**

58 ***Objectives***

59 Develop and validate a thorough exposure questionnaire to comprehensively explore crystalline  
60 silica (SiO<sub>2</sub>) exposure in the general population (gender-specific, occupational and non-  
61 occupational) and in patients with autoimmune diseases (Rheumatoid arthritis (RA), Systemic  
62 sclerosis (SSc)).

63 ***Methods***

64 Lifetime exposures to SiO<sub>2</sub> in occupational and non-occupational settings were assessed using a  
65 thorough exposure questionnaire. The questionnaire was applied to a general population panel  
66 (N=2,911) sampled from the French rolling census, and to unselected patients with SSc (N=100)  
67 and RA (N=97). Global (GES), occupational (OES) and non-occupational (NOES) exposure  
68 scores were assessed in SSc and RA patients, and compared to up to 4 controls from the general  
69 population, matched by age group, sex and tobacco consumption.

70 ***Results***

71 Patients had higher GES than their matched controls (SSc: p=0.001; RA: p<0.0001) due to higher  
72 OES (p<0.0001 for SSc and RA). Men had higher GES than women (SSc: p<0.0001; RA: p=0.002)  
73 due to higher OES (p<0.0001 for SSc and RA). The NOES did not differ between men and  
74 women.

75 In SSc patients: Men had higher GES than controls (p<0.0001). Men and women with SSc had  
76 higher OES than controls (p<0.0001).

77 In RA patients: GES and OES were higher in both men (p=0.00521; p<0.0001) and women  
78 (p<0.0001; p<0.0001) than in their respective controls. Women had higher NOES than controls  
79 (p=0.045).

80 ***Conclusion***

81 The lifetime SiO<sub>2</sub> exposure gap between RA and SSc patients and controls was substantially due to  
82 occupational exposure. In both diseases, men had higher exposure scores than women.

83

84 **Clinical trial registration number (for all RCT's):** NA

85

86 **Keywords** (up to 10 – please note that the word count refers to individual words, not phrases)

87 Crystalline silica / Systemic sclerosis / Rheumatoid arthritis / Occupational and non-occupational  
88 exposure

89

90 **Key messages** (up to 3, maximum 15 words each)

91 1 – Patients with SSc and RA had significant lifetime occupational overexposure to SiO<sub>2</sub>.

92 2 – Occupational exposure in men with SSc or RA was higher than in women.

93 3 – Physicians should carefully assess past silica exposure, which could unlock financial  
94 compensation for patients.

95

96 **References** (up to 50): 44

97

98 **Tables/figures:** 5 included in the article

99 + 2 Texts, 1 Figure & 2 Tables in Supplementary Material

100

101 **Word count:** 3,885

102

103

## 104 **INTRODUCTION**

105 Crystalline silica (or silicon dioxide, SiO<sub>2</sub>), mainly occurring as the polymorphs quartz (the  
106 most common in nature and manufacturing processes), cristobalite and tridymite, is one of the  
107 most ubiquitous environmental components.

108 Resulting from exposure to SiO<sub>2</sub>, silicosis was initially defined in 1930 at a conference  
109 jointly organized by the International Labour Organization and the Transvaal Chamber of Mines,  
110 a South African mining-industry employer organization (1,2). Ensuing decades saw the  
111 involvement of SiO<sub>2</sub> highlighted in pulmonary alveolar proteinosis and systemic autoimmune  
112 diseases such as systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus (SLE), and  
113 ANCA-associated vasculitis (AAV) (3–5). The link between RA and SiO<sub>2</sub> has been well  
114 documented in large cohorts of construction workers (6). Exposure to SiO<sub>2</sub> may contribute to  
115 “decreasing the threshold for the development of autoimmune disease in general”, but could also  
116 trigger the onset of some clinical manifestations of these diseases (7). The association between SiO<sub>2</sub>

117 and SSc, the rheumatic disease with the highest individual mortality rate, has been continuously  
118 reported in several case-control and cohort studies (8,9). Studies conducted since 2000 have  
119 strengthened the association of SiO<sub>2</sub> and systemic autoimmune diseases, especially for exposure  
120 from cutting, polishing or bevelling new high-silica content materials (10,11), out of the mining  
121 sector (12,13).

122 Large-scale case-control or cohort studies exploring the association between SiO<sub>2</sub> and  
123 autoimmunity rarely (if ever) consider non-occupational exposures. The general difficulty of  
124 producing a standard measure of “normal” exposure to crystalline silica (14) reflects the lack of  
125 standardized questionnaires able to explore SiO<sub>2</sub> exposure as a whole, and to identify the sources  
126 of exposure over a lifetime in the general population and in people with autoimmune diseases.

127 The objective of this study was to develop and validate a thorough exposure questionnaire  
128 to comprehensively explore SiO<sub>2</sub> exposure in the general population (gender-specific, occupational  
129 and non-occupational). First, we administered the questionnaire to a large representative sample of  
130 the French general population (sampled from the general French rolling census). Next, we assessed  
131 and compared silica exposure in patients diagnosed with SSc or RA versus the general population.

132

## 133 **MATERIAL AND METHODS**

134

### 135 **Assessment of exposure to mineral dusts**

#### 136 *Designing the questionnaire*

137 The Dust Exposure Life-Course Questionnaire (DELCQ) mainly aimed to assess exposure  
138 to SiO<sub>2</sub>. To reach sufficient sensitivity, we prepared a list of questions based on the inventory of  
139 exposure activities made by the Working Group on the Evaluation of Carcinogenic Risks to  
140 Humans (15). To develop a thorough inquiry, we supplemented this large list of exposure activities  
141 by broadening their spectrum with medical or statistical surveys of the general population (16–18).  
142 We added in data from the literature on exposure to SiO<sub>2</sub> and inorganic particles in occupational  
143 or environmental settings, including clinical case reports (on clay eating (19), exposure to cat litter  
144 dust (20), talcum spreading on abraded skin (21), and air contamination by working clothes as in  
145 the case of asbestos (22)), as well as metrological and epidemiological questions on the average  
146 silica concentration in ambient air (14).

147 Drawing on lessons from the sociology of labor (23), we avoided asking people about pre-labelled  
148 occupations/“jobs”. DELCQ is distinctive in helping respondents designate the actual “activities”

149 they performed in their various occupations. To this end, we phrased matter-of-fact questions that  
150 explicitly and precisely referred to products, gestures, equipment, and contexts in which substances  
151 were handled, and that used the familiar and/or commercial names of products. The wealth of  
152 questions helped maximize the sensitivity of the questionnaire, while their evocative nature  
153 maximized its specificity.

154 As far as we know, DELCQ unprecedentedly addresses both occupational *and* non-  
155 occupational exposure (in two consecutive modules) over a lifetime.

156 Whereas most questions focused on occupational and non-occupational exposure to silica,  
157 some additional ones explored exposure to other inorganic particles. Two questions were about  
158 (active and passive) exposure to asbestos at work, and two others probed non-occupational  
159 exposure to asbestos, and other mineral, metallic or wood particles (shaking, washing, ironing...  
160 dusty working clothes). At the end of each of the two modules, respondents could add any other  
161 exposure to silica or other mineral, metallic, wood, leather, diesel or soot particles they might have  
162 experienced.

### 163 *Content of DELCQ, & quantification of exposure*

164 The questionnaire evaluated:

165 1) Sociodemographic and socioeconomic characteristics, highest degree earned, current or  
166 latest employment status, and professional skills.

167 2) Health status through: a) the Mini-European Health Module (24) which comprises 3  
168 questions on *i*) self-assessed health status (25), *ii*) presence/absence of at least one current chronic  
169 disease defined as lasting or likely to come back during 6 months or more, *iii*) functional limitations  
170 in daily activities because of health issues; b) specific questions about diseases of interest (silicosis,  
171 tuberculosis, emphysema, asthma, chronic obstructive pulmonary disease (COPD), asbestosis or  
172 pleural plaques, idiopathic pulmonary fibrosis, lung cancer, sarcoidosis, other respiratory diseases,  
173 RA, SSc, SLE, other connective tissue diseases, vasculitis, and any disease that the respondent  
174 thought or had been told may be caused/aggravated by exposure to crystalline silica or other  
175 inorganic particles; c) the administrative recognition of an occupational disease, or of a long-term  
176 chronic disease associated with a special financial status in the French social welfare system; d)  
177 medical leaves and hospitalizations (at least one night in the past 12 months); e) lifetime tobacco  
178 use (cigarette pack-years); f) height, weight; g) sniffing practices (cocaine or other inhaled drugs,  
179 scouring powders); h) drug injection.

180 The questionnaire included 90 questions about occupational exposure and 47 about non-  
181 occupational exposure. While they thoroughly explored numerous forms of exposure to SiO<sub>2</sub>, the

182 two modules also sought to quantify the exposure level according to the respondent's self-  
183 assessment. For more than 95% of the questions, the respondent had to answer a first screening  
184 question exploring an occupational or non-occupational setting *potentially* at risk of exposure to  
185 SiO<sub>2</sub>. If answered in the affirmative, one or more questions followed to assess whether the  
186 respondent had been involved in specific exposure activities in this setting, and if so, the cumulative  
187 duration of exposure in his/her life (<1 year; [1;5[ years; >= 5 years) and the level of protection  
188 (mainly respiratory but also cutaneous and ophtalmological) from dust he/she had used (from (i)  
189 never protected or protection always ineffective; to iii) always effectively protected)  
190 (**Supplementary Text 1**). A dust exposure score was then calculated based on the duration and  
191 the effectiveness of protections against dust (see Suppl. Fig. S2 in (26)). We applied this inquiry  
192 approach to most of the situations reviewed, predominantly occupational exposure (48 different  
193 occupational scenarios and 18 non-occupational scenarios). Alternatively, the first relevant  
194 question could directly focus on a specific exposure activity, without the first filter question about  
195 the at-risk setting (**Supplementary Text 2**). Assessing the level of protection was not always  
196 relevant, notably in non-occupational contexts. For instance, the use of talcum powder on abraded  
197 skin was by definition not associated with cutaneous protection. In such (exceptional) situations,  
198 the number of points we added to the dust score was equivalent to that of an exposure without  
199 protection.

200 Our method enabled the calculation of a global exposure score (GES) encompassing all  
201 exposures, which could be broken down into an occupational exposure score (OES) and a non-  
202 occupational exposure score (NOES) (GES=OES+NOS), or into any specific exposure score.

203 Throughout the questionnaire, we did not display the possibility to refuse to answer or say  
204 "I do not know" at first. Both in the telephone and face-to-face interviews and on tablets, our first  
205 proposal only consisted in response items. This ensured a high response rate. If a respondent finally  
206 decided to refuse to answer or did not know how to, he/she could get around the question. By  
207 proceeding this way, we hardly got missing values. In particular, there were no missing values  
208 among the data the exposure scores are based upon.

209

## 210 **Fieldwork and questionnaire processing**

### 211 ***1 – French general population***

#### 212 *Presentation and processing*

213 Panelists were sampled from the general population by the French National Statistical  
214 Institute (INSEE) using national rolling census data. They answered the questionnaire in 2014

215 (ELIPSS-(Longitudinal Online Social Science Survey)-Silice 1(n=825) and in 2016 ELIPSSilice2  
216 (n=2,937) (**Supplementary Figure 1**). The questionnaire was self-administered on tablets. Most  
217 of the time, answering the questionnaire took between 35 and 40 minutes. (See **Supplementary**  
218 **Table 1** on response rates).

### 219 *Exploration of self-declared RA*

220 Given that respondents might confuse self-declared RA with other conditions (e.g.  
221 “arthritis” or “osteoarthritis”), for ELIPSSilice2 we revised our questionnaire with the following  
222 addition regarding RA: “Did a physician diagnose you with this disease using the term ‘rheumatoid  
223 arthritis?’”. As a result, the statistical analyses including data on self-declared diseases encompassed  
224 the 2,739 people who responded to at least ELIPSSilice2 (and potentially to ELIPSSilice1 & 2).  
225 We thus sought to eschew results based on false RA positives (27).

226

## 227 ***2 – Populations of patients from expert centers, diagnosed with systemic autoimmune*** 228 ***diseases***

### 229 *Patient populations*

230 SSc patients in the department of Internal Medicine and Clinical Immunology of Rennes  
231 University Hospital who met the ACR/EULAR 2013 classification criteria for the disease were  
232 consecutively included in the study between 2016 and 2018 (26). RA patients in the department of  
233 Rheumatology of Avicenne Teaching Hospital (GHUPSSD, APHP, Bobigny, France) were  
234 included in 2016, and all met the 2010 ACR/EULAR classification criteria for RA. For SSc and  
235 RA patients, questionnaires were administered by phone or in face-to-face interviews by 4 trained  
236 evaluators. The interview usually lasted 45 to 60 minutes. (See **Supplementary Table 1** on  
237 response rates and data collection methods). One hundred patients with SSc (median age=63.0  
238 years, IQR=17.0) and 97 patients with RA (median age=60.0 years, IQR=16.0) were included.

239

### 240 **Ethics**

241 The databases were declared to the French authorities under the following entry: Comité  
242 consultatif sur le traitement de l'information en matière de recherche (CCTIRS) n° 08-015bis and  
243 n°12-263bis, Commission Nationale de l'Informatique & des Libertés (CNIL, France), decision  
244 DR 2012 525 and decision 1980161v0. All SSc and RA patients gave their informed consent.  
245 Local review boards (in Rennes and Bobigny) approved the studies.

246

## 247 **Statistical methods**

248 Scores (GES, OES, NOES) are expressed as median (IQR) & mean (+/-SD). Scores  
249 obtained by patients diagnosed with RA or SSc were compared to those of matched controls using  
250 the Wilcoxon test (level of significance:  $p < 0.05$ ). For each patient, we randomly sampled up to 4  
251 controls among ELIPSSilice2 respondents in strata matched by age range, sex and tobacco  
252 consumption (number of pack-years). Two situations were considered: 1) *Scenario #1*: controls were  
253 selected among people “declaring not to have the disease carried by the matched patient”. This  
254 meant that controls could have (or have had) *another* chronic condition; 2) *Scenario #2*: controls  
255 were selected among people “declaring to have (or have had) *none* of the chronic conditions (i.e.  
256 neither the disease of the matched patient, *nor any other* chronic conditions evaluated in the  
257 questionnaire)”. The data were tabulated with SAS v9.4, R and RStudio 2022.07.0 software.

258

259

## 260 **RESULTS**

261

### 262 **1 – Exposure scores in the general population**

263 Among the 2,911 panelists who responded to ELIPSSilice1 only, ELIPSSilice2 only, or  
264 ELIPSSilice1 & 2, the lifetime prevalence of self-declared SiO<sub>2</sub> exposure (i.e. a strictly positive  
265 GES) was 90.7%, with a mean exposure level of 17.97 (SD=20.4), and a median exposure level of  
266 12.0 (IQR=20.0) (**Supplementary Table 2**). The prevalence of exposure in occupational settings  
267 (OES>0) was 46.0%, and the prevalence of exposure in non-occupational settings (NOES>0) was  
268 87.9%.

269 The dust exposure score varied according to the age of the respondent at the time of the  
270 questionnaire (**Figure 1**). Among the 2,911 panelists of ELIPSSilice1 & 2, the GES reached a  
271 maximum of 21 points for people aged 55-59, and decreased thereafter. The OES decreased after  
272 age 65, while NOES showed a slight and gradual decrease after age 60-64.

273

### 274 **2 – Case-control comparison of SiO<sub>2</sub> exposure: respondents in the general population 275 *versus* patients diagnosed with systemic diseases**

276 Median GES in SSc and RA patients were 23.0 (IQR=29.0) and 26.0 (IQR=25.0),  
277 respectively (**Table 1**). Median OES were 9.5 (IQR=20.0) and 10 (IQR=15.0), and median NOES  
278 were 12.0 (IQR=16.5) and 15.0 (IQR=13.0), again in SSc and RA patients respectively, providing

279 a compared profile of the two diseases in which higher GES in RA appeared to be supported by  
280 higher NOES, whereas exposure in occupational contexts would be more specific to SSc.  
281 Regardless of the method used to sample matched controls (Scenarios #1 & 2), SSc patients and  
282 RA patients had significantly higher GES than the controls. For both diseases, this significant  
283 difference stemmed from a significantly higher occupational exposure, whereas non-occupational  
284 exposure did not differ between patients and controls.

285

286

### 287 **3 – Relationships between sex and SiO<sub>2</sub> exposure in SSc and RA**

288 Among patients diagnosed with SSc and patients diagnosed with RA, male patients had  
289 significantly higher GES than female patients (**Table 2**). This difference stemmed from a  
290 significantly higher exposure for male patients in occupational settings. In non-occupational  
291 settings, NOES in female and male patients did not differ. The comparison of exposure levels  
292 between SSc and RA by sex showed that SSc male patients had higher GES than RA male patients  
293 as a result of higher OES, whereas female RA patients had higher GES than SSc female patients  
294 by virtue of a higher NOES (**Table 2**). In the general population (ELIPSSilice1 & 2), median GES  
295 in women and men were 9.0 (IQR=15.0) and 15.0 (IQR=27.0), respectively (**Table 3**). Median  
296 OES were 0.0 (IQR=4.0) and 4.0 (IQR=16.0), and median NOES were 7.0 (IQR=11.0) and 9.0  
297 (IQR=15.0) in both sexes, respectively.

298 We stratified cases and controls by sex, age, and tobacco use (**Table 4**). Among SSc patients,  
299 only men (and not women) had higher GES than their controls. Yet both women and men with  
300 SSc had significantly higher OES than their matched controls, while NOES did not differ. GES  
301 and OES were significantly higher for both male and female RA patients, compared with their  
302 matched controls. NOES were significantly higher only in women with RA versus their matched  
303 controls. These results are conservative, as they are drawn from Scenario#1, for which the  
304 DELCQ's gap between diagnosed patients and respondents was lower (**Table 1**).

305

306

## 307 **DISCUSSION**

308 This study extensively explored SiO<sub>2</sub> exposure in the French general population and in  
309 populations with two autoimmune diseases repeatedly associated with this exposure in the  
310 literature. The use of a novel inquiry tool based on social science and statistical skills enabled a  
311 thorough assessment of lifetime silica exposure. Importantly, the questionnaire focused on the

312 actual sources and circumstances of exposure, thereby providing unprecedented accuracy in  
313 exposure assessment.

314 Compared to other analogous inquiry tools (16, 28), this questionnaire is unique in  
315 endeavouring to capture occupational *and non-occupational* exposures, also via thorough questioning.

316 The high prevalence of a history of exposure to silica found in this survey (90.7%) underscores  
317 the ubiquity of occupational and non-occupational exposure to one of the most common mineral  
318 components of the earth crust, when a sensitive questionnaire is used. The only French statistical  
319 survey (SUMER, Medical Follow-Up of Exposure to Occupational Hazards) that has measured it  
320 (in 1994, 2003, 2010, 2016-2017) considers only occupational exposure to SiO<sub>2</sub> in the general  
321 population, and allows occupational physicians to select “yes” only for workers exposed during the  
322 latest working week (29). This lack of systematicity (30) has yielded the excessively low finding that  
323 a paltry 1.4% of salaried workers are exposed to silica (16).

324 Other nationwide studies on SiO<sub>2</sub> exposure (28,31,32) have also solely focused on occupational  
325 exposure. The prevalence of SiO<sub>2</sub> exposure in those studies ranged from 17% (in men) (31) to  
326 1.0% (in women) (28), depending on several parameters (e.g. cross-sectional survey *versus* cohort,  
327 exposure assessed in current job *versus* all *cursus laboris*, assessment via exposure-job matrices). In  
328 the Danish nationwide survey (31), higher exposure levels were associated with older age. The same  
329 trend appeared in our work, although respondents over 64 years old reported lower OES than  
330 patients aged 45-64. This could be attributable to the retrospective nature of the evaluation,  
331 introducing memory biases (analogous to those studied in other fields of research such as  
332 victimization (33,34)) in addition to a survivor bias: since respondents with higher exposure may  
333 have died sooner than those without it, they would be underrepresented among respondents older  
334 than 65 in this study. As for the memory biases, we may hypothesize that once a person has no  
335 longer a professional activity, it is more difficult for her/him to remind specific memories about  
336 occupational exposures.

337 To validate the relevance of DELCQ and its content validity, we conducted a case-control  
338 study comparing patients with known systemic autoimmune disorders from expert centers with  
339 controls matched by age range, sex and tobacco consumption (number of pack-years) from the  
340 ELIPSSilice2 survey. Our two sampling *scenarii* aimed to limit controls’ selection bias. In both  
341 *scenarii*, the GES and OES from cases (both SSc and RA) were higher than those from controls.  
342 This result confirms findings from previous studies in the literature, supporting the relevance of  
343 the questionnaire and its ability to discriminate patients from controls.

344 Our results suggest that the difference between patients with autoimmune diseases and controls  
345 is substantially due to occupational exposure, as NOES did not differ between controls and patients  
346 (except for women and their matched controls in RA), in the two *scenarii*. The NOES were generally  
347 numerically higher than OES in both controls and patients. This suggests that score calculation  
348 methods identically applied to OES and NOES may not be completely relevant to quantifying non-  
349 occupational cumulative exposure. More specifically, since non-occupational exposures often  
350 occur without protection (e.g. mud bathing, clay eating, etc.), the points added to the NOES  
351 (considering this lack of protection) may create an excessive rise in the NOES vis-à-vis the OES.  
352 Moreover, considering a cumulative exposure of more than 5 years as a single category might also  
353 overestimate the NOES. A continuous quantification of the cumulative duration of exposure is  
354 theoretically preferable. But how could respondents actually answer? Using our calculation  
355 methods, we can trust the comparability of levels of (respectively) GES, OES and NOES between  
356 the various people (patients and respondents in the general population) in our samples, as in all  
357 cases inter-individual comparisons were made by adding up the same components of the exposure  
358 scores.

359 With regard to gender, significant lifetime overexposure to SiO<sub>2</sub> in the workplace appears for  
360 both women and men suffering from RA and SSc in comparison with their matched controls.  
361 Interestingly, NOES in women with RA were higher than in controls, unlike SSc patients. This  
362 unprecedented result might suggest that non-occupational silica exposure for women with RA  
363 could contribute to the pathogenesis and onset of their disease. We therefore subsequently  
364 explored which particular non-occupational situations are responsible for silica exposure in female  
365 RA patients in another study (Sigaux *et al.*, to be published).

366 Our inquiry method consisted of a retrospective reconstitution of exposure. This assessment  
367 is not equivalent to an empirical “live” measure of exposure (e.g. dust level measurements in the  
368 workplace). However, the latter measurements also have limitations, since they do not account for  
369 the presence/absence/effectiveness of potential respiratory protection equipment (35).

370 The questionnaire’s methodological assets enable it to thoroughly screen sources of extra-  
371 occupational exposure. However, the cumulative dose of non-occupational exposure can be even  
372 more difficult to unearth for respondents than their cumulative occupational exposure.  
373 Considerable memory effort is required to estimate the time spent on hobbies likely linked to the  
374 exposures of interest and involving activities performed in short or discontinuous periods over a  
375 lifetime. The case-control approach is also limited insofar as cases (SSc or RA) were included from  
376 a single center for each disease, whereas controls were selected from the general French population

377 (national rolling census). Regional discrepancies may exist in the prevalence of silica exposure, and  
378 the design of the case-control study did not take these into account.

379 Moreover, data collection methods varied between RA and SSc patients (phone calls or face-  
380 to-face interviews by 4 trained evaluators) and control respondents (ELIPSSilice2 survey, self-  
381 administered questionnaires on tablets). We verified that this potential evaluation bias was limited,  
382 and particularly that a self-completion of the questionnaire offered sufficient guarantees in terms  
383 of specificity and sensibility. These results have been published elsewhere (36) showing that: a)  
384 The differences between the exposure scores of people reporting themselves as having a disease  
385 (ELIPSSilice1 & 2) and patients with a disease diagnosed by a physician (SSc, RA) suggested a  
386 lower sensitivity of self-questioning of exposures but without compromising the relevance of the  
387 self-collected data on exposure. b) Panelists interrogated twice (ELIPSSilice1 & 2) tended to have  
388 growing GES (above all because of an increase in OES), suggesting that, as time goes by between  
389 two waves of the survey, respondents manage to report new exposure that occurred in the  
390 meantime. c) In ELIPSSilice 1 & 2, respondents who self-declared having a disease had higher  
391 exposure scores as compared to those who did not declare any disease, confirming the results based  
392 on questionnaires with RA and SSc patients. d) To minimize false positive cases from too loose  
393 self-questioning on RA, we added the question: “Did a physician diagnose you with this disease  
394 using the term ‘rheumatoid arthritis?’”. All these data suggest that the self-completion of the  
395 questionnaire was not a major bias in this study.

396 One of DELCQ’s major strengths is its methodological approach to questioning respondents.  
397 We sought to overcome several challenges in order to get sufficiently sensitive and specific  
398 responses, even when the questionnaire was self-administered. Questions were purposely  
399 numerous, and their wording was carefully chosen. The first challenge is that these relationships  
400 are part of a much broader landscape of knowledge uncertainty: science may be powerless when  
401 confronted with the production of ignorance more or less directly led by firms with huge economic  
402 interests in blurring and underestimating hazards (37–39). Second, at the individual level of  
403 knowledge, actual health hazards may be underestimated even in a well-known work environment.  
404 As observed with subcontracted workers (40), “virility as a defensive strategy to deny occupational  
405 risk”, family arrangements, gambles on the future, and obviously the obligation to earn one’s living  
406 may lead workers to “ignore” health hazards and corresponding preventive measures. Our  
407 questionnaire therefore includes some analogous questions multiple times to bring back factual  
408 memories, whether it is conducted by an external evaluator or self-administered.

409

410           **CONCLUSION**

411           Our results confirm that SiO<sub>2</sub> hazards *specifically* involve exposure *in occupational activities*.  
412 This makes a compelling case for medical training programs. Physicians should not overlook such  
413 occupational risks when recording their patients' medical histories, even for rare disorders such as  
414 SSc. Lifetime occupational exposure to SiO<sub>2</sub> is higher in RA and SSc patients *versus* the general  
415 population, suggesting it may be either an environmental cause of the diseases or a factor in the  
416 severity of the disease phenotypes, often observed in male patients, or even both (8, 39). Further  
417 research is needed on sex/gender-specific disease severity and SiO<sub>2</sub> overexposure in both RA and  
418 SSc. Moreover, some pieces of evidence keep accumulating about the deleterious role played by  
419 SiO<sub>2</sub> exposure in SSc male patients (42,43). Our results suggest for the first time that extra-  
420 occupational exposure to SiO<sub>2</sub> may contribute to the onset of RA in women.

421 Such results suggest that the sex variable should not be considered a final result, but rather that the  
422 differences between men and women should be probed. Differences between men and women in  
423 connective tissue diseases in terms of aetiology and severity should be considered as a “black box”  
424 (44) while deconstructing the gender gap. Uncovering different exposure levels and contexts  
425 between the sexes may participate in answering the question: *what* differentiates men and women  
426 with a systemic disease from both a biological and sociological perspective?

427

428           **References**

- 429           1.    ILO. Silicosis. Records of the International Conference held at Johannesburg (13-27 August  
430           1930). Geneva: ILO; 1930. 758 p. (Studies and Reports, Series F, Industrial Hygiene).
- 431           2.    Rosental PA, Rosner D, Blanc PD. From Silicosis to Silica Hazards: An Experiment in  
432           Medicine, History, and the Social Sciences. American Journal of Industrial Medicine.  
433           2015;(58):S3-5.
- 434           3.    Rafnsson V, Ingimarsson O, Gunnarsdottir H. Association between exposure to crystalline  
435           silica and risk of sarcoidosis. Occupational and Environmental Medicine. 1998;(55):657-60.
- 436           4.    Lescoat A, Cavalin C, Macchi O, Jégo P, Rosental PA. Silica-associated systemic sclerosis in  
437           2017: 60 years after Erasmus, where do we stand? Clinical Rheumatology. 17 févr 2017;
- 438           5.    Caplan A. Certain Unusual Radiological Appearances in the Chest of Coal-Miners Suffering  
439           from Rheumatoid Arthritis. Thorax. 1953;8(29):29-37.
- 440           6.    Blanc PD, Jarvholm B, Torén K. Prospective Risk of Rheumatologic Disease Associated with  
441           Occupational Exposure in a Cohort of Male Construction Workers. The American Journal  
442           of Medicine. oct 2015;128(10):1094-101.

- 443 7. Parks CG, d'Aloisio AA, Sandler DP. Early Life Factors Associated with Adult-Onset  
444 Systemic Lupus Erythematosus in Women. *Frontiers in Immunology*. 31 mars 2016;(7):1-7.
- 445 8. Patel S, Morrisroe K, Proudman S, Hansen D, Sahhar, Sim M, et al. Occupational silica  
446 exposure in an Australian systemic sclerosis cohort. *Rheumatology (Oxford, England)*  
447 [Internet]. 12 janv 2020 [cité 12 juill 2022];59(12). Disponible sur:  
448 <https://pubmed.ncbi.nlm.nih.gov/32911541/>
- 449 9. Marie I, Menard J, Duval-Modeste A, Joly P, Dominique, Bravard P, et al. Association of  
450 occupational exposure with features of systemic sclerosis. *Journal of the American Academy*  
451 *of Dermatology* [Internet]. mars 2015 [cité 12 juill 2022];72(3). Disponible sur:  
452 <https://pubmed.ncbi.nlm.nih.gov/25582539/>
- 453 10. León-Jiménez A, Hidalgo-Molina A, Conde-Sánchez MÁ, Pérez-Alonso A, Morales-Morales  
454 JM, García-Gámez EM, et al. Artificial Stone Silicosis: Rapid Progression Following  
455 Exposure Cessation. *Chest*. sept 2020;158(3):1060-8.
- 456 11. Shtraichman O, Blanc PD, Ollech J, Fridel L, Fuks L, Fireman E, et al. Outbreak of  
457 autoimmune disease in silicosis linked to artificial stone. *Occupational Medicine*.  
458 2015;(65):444-50.
- 459 12. Ozmen CA, Nazaroglu H, Yildiz T, Bayrak AH, Senturk S, Ates G. MDCT Findings of  
460 Denim-Sandblasting-Induced Silicosis: a cross-sectional study. *Environmental Health*.  
461 2010;9:1-8.
- 462 13. Quail T. Overview of Silica-Related Clusters in the United States: Will Fracking Operations  
463 Become the Next Cluster? *Journal of Environmental Health*. févr 2017;79(6):20-7.
- 464 14. National Center for Environmental Assessment, US Environmental Protection Agency.  
465 Ambient Levels and Noncancer Health Effects of Inhaled Crystalline and Amorphous Silica:  
466 Health Issue Assessment. Research Triangle Park, North Carolina: US EPA; 1996 p. 177.
- 467 15. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Silica Dust,  
468 Crystalline, in the Form of Quartz or Cristobalite. In: World Health Organization Press.  
469 Geneva; 2012. p. 355-405. (Monographs on the Evaluation of Carcinogenic Risks to Humans;  
470 vol. 100C).
- 471 16. Matinet B, Rosankis É, Léonard M. Les exposition aux risques professionnels. Les produits  
472 chimiques. *Synthèse·Stat' DARES*. juill 2020;(32):323.
- 473 17. Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, et al. BioCAST/IFCT-1002:  
474 epidemiological and molecular features of lung cancer in never-smokers. *Eur Respir J*. mai  
475 2015;45(5):1403-14.
- 476 18. Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a  
477 review of the evidence and exposure assessment methods in population- and clinic-based  
478 studies. *Lupus*. 1 nov 2006;15(11):728-136.
- 479 19. Comstock G, Keltz H, Senzer D. Clay Eating and Sarcoidosis A Controlled Study in the State  
480 of Georgia. *American Review of Respiratory Disease*. 1 nov 1961;84(5P2):130-4.


- 481 20. Drent M, Wijnen P, Boots A, Bast A. Cat litter is a possible trigger for sarcoidosis. *European*  
482 *Respiratory Journal*. 2012;39(1):221-2.
- 483 21. Vincent M, Chemarin C, Peyrol S, Thivolet F, Champagnon B. Application cutanée de talc et  
484 sarcoïdose. À propos de deux cas. *Revue des Maladies Respiratoires*. 2004;(21):811-4.
- 485 22. Wagner J, Sleggs C, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the  
486 North Western Cape Province. *British Journal of Internal Medicine*. 1960;17(4):260-71.
- 487 23. Friedmann G, Naville P. *Traité de sociologie du travail*. Armand Colin. Vol. tome 1. Paris;  
488 1961. 467 p.
- 489 24. Eurostat. European Health Interview Survey (EHIS wave 2). Methodological manual  
490 [Internet]. Luxembourg: Eurostat. European Commission; 2013. 193 p. (Methodologies and  
491 Working Papers). Disponible sur:  
492 [https://ec.europa.eu/eurostat/documents/3859598/5926729/KS-RA-13-018-](https://ec.europa.eu/eurostat/documents/3859598/5926729/KS-RA-13-018-EN.PDF/26c7ea80-01d8-420e-bdc6-e9d5f6578e7c)  
493 [EN.PDF/26c7ea80-01d8-420e-bdc6-e9d5f6578e7c](https://ec.europa.eu/eurostat/documents/3859598/5926729/KS-RA-13-018-EN.PDF/26c7ea80-01d8-420e-bdc6-e9d5f6578e7c)
- 494 25. Miilunpalo S, Vuori I, Pasanen M, Urponen H. Self-rated health status as a health measure -  
495 the predictive value of self-reported status on the use of physician services and on mortality  
496 in the working age population. *Journal of Clinical Epidemiology*. mai 1997;50(5):517-28.
- 497 26. Ballerie A, Cavalin C, Lederlin M, Nicolas A, Garlantézec R, Jouneau S, et al. Association of  
498 silica exposure with chest HRCT and clinical characteristics in systemic sclerosis. *Seminars in*  
499 *Arthritis and Rheumatism*. 1 oct 2020;50(5):949-56.
- 500 27. Guillemin F, Saraux A, Guggenbuhl P, Roux C, Fardellone P, Le Bihan E, et al. Prevalence  
501 of rheumatoid arthritis in France: 2001. *Annals of the Rheumatic Diseases*.  
502 2005;64(10):1427-30.
- 503 28. Carey R, Driscoll TR, Peters S, Glass DC, Reid A, Benke G, et al. Estimated prevalence of  
504 exposure to occupational carcinogens in Australia (2011–2012). *Occupational and*  
505 *Environmental Medicine*. 2014;(71):55-62.
- 506 29. Cavalin C, Rosental PA, Vincent M. Peut-on prendre la mesure du risque silice ? Enquêtes  
507 santé, enquêtes travail et outils de veille sanitaire. In: *Actes du colloque Sondages* [Internet].  
508 ENSAI, Rennes; 2012. p. 21. Disponible sur: [http://sondages2012.ensai.fr/wp-](http://sondages2012.ensai.fr/wp-content/uploads/2011/01/Actes-colloque-Sondages-2012_Cavalin_Rosental_Vincent.pdf)  
509 [content/uploads/2011/01/Actes-colloque-Sondages-2012\\_Cavalin\\_Rosental\\_Vincent.pdf](http://sondages2012.ensai.fr/wp-content/uploads/2011/01/Actes-colloque-Sondages-2012_Cavalin_Rosental_Vincent.pdf)
- 510 30. Lescoat A, Ballerie A, Lecureur V, Belhomme N, Cazalets C, Jouneau S, et al. The neglected  
511 association of crystalline silica exposure and systemic sclerosis. *Rheumatology (Oxford)*. 1  
512 déc 2020;59(12):3587-8.
- 513 31. Boudigaard Sh, Schlünssen V, Vestergaard J, Søndergaard K, Torén K, Peters S, et al.  
514 Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic  
515 diseases: a nationwide cohort study. *International journal of epidemiology* [Internet]. 30 août  
516 2021 [cité 30 sept 2021];50(4). Disponible sur: <https://pubmed.ncbi.nlm.nih.gov/33462590/>
- 517 32. Si S, Carey RN, Reid A, Driscoll TR, Glass DC, Peters S, et al. The Australian Work  
518 Exposures Study: Prevalence of Occupational Exposure to Respirable Crystalline Silica. *The*  
519 *Annals of occupational hygiene* [Internet]. juin 2016 [cité 13 juill 2022];60(5). Disponible sur:  
520 <https://pubmed.ncbi.nlm.nih.gov/26888888/>

- 521 33. Skogan WG. Issues in the Measurement of Victimization. Washington DC: United States  
522 Department of Justice, National Institute of Justice; 1981. 35 p.
- 523 34. Grémy JP. Les « défaillances de la mémoire » dans les enquêtes de victimation. Bulletin de  
524 méthodologie statistique. avr 2007;(94):39-56.
- 525 35. Brown T, Rushton L. Mortality in the UK industrial silica sand industry: 1. Assessment of  
526 exposure to respirable crystalline silica. Occupational and Environmental Medicine.  
527 2005;62(7):442-5.
- 528 36. Cavalin C, Catinon M, Macchi O, Vincent M, Rosental PA, et al. Expositions aux particules  
529 inorganiques : comment poser la question ? in Duwez Emmanuelle, Mercklé Pierre (dir.). In:  
530 Un panel français L'Étude longitudinale par internet pour les sciences sociales (ELIPSS).  
531 Paris: Éditions de l'INED; 2021. p. 185-212. (Grandes enquêtes).
- 532 37. Proctor RN, Schiebinger LL. The making and unmaking of ignorance. Stanford: Stanford  
533 University Press; 2008. VIII-298.
- 534 38. Boudia S, Jas N. Gouverner un monde toxique. Versailles: Quae; 2019. 121 p.
- 535 39. Musu T, Sapir M. Will the Silica Agreement foil EU legislation? HESA Newsletter. oct  
536 2006;(30-31):4-8.
- 537 40. Ghis Malfilatre M. The impossible confinement of nuclear work. Professional and Family  
538 Experiences of Subcontracted Workers Exposed to Radioactivity. Travail et Emploi Special  
539 Edition. 2017;103-25.
- 540 41. Ballerie A, sld Lescoat A. Impact de l'exposition aux particules inorganiques sur la sévérité et  
541 les caractéristiques scanographiques de l'atteinte pulmonaire au cours de la Sclérodémie  
542 systémique. [Rennes]: Rennes 1; 2018.
- 543 42. Smith V, Vanthuyne M, Vander Cruyssen B, Van Praet J, Vermeiren F, Smets H, et al. Over-  
544 representation of construction-related occupations in male patients with systemic sclerosis.  
545 Annals of the Rheumatic Diseases. 1 oct 2008;67(10):1448-50.
- 546 43. Muntyanu A, Milan R, Rahme E, LaChance A, Ouchene L, Cormier M, et al. Exposure to  
547 silica and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma  
548 Research Group. Frontiers in Medicine [Internet]. 2022 [cité 23 oct 2022];9. Disponible sur:  
549 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556811/>
- 550 44. Shim JK. Understanding the routinised inclusion of race, socioeconomic status and sex in  
551 epidemiology: the utility of concepts from technoscience studies. Sociology of Health &  
552 Illness. 2002;24(2):129-50.
- 553
- 554

555  
556  
557  
558  
559  
560

### Tables & Figures

Figure 1: Exposure scores from DELCQ, according to the age of ELIPSSilice1&2 panelists



561  
562  
563  
564  
565  
566

**Table 1: Compared exposure scores from DELCQ between diagnosed (RA, SSc) patients and controls randomly sampled in ELIPSSilice2**

Exposure scores	SSc Scenario #1 <sup>1</sup>			SSc Scenario #2 <sup>2</sup>			RA Scenario #1 <sup>1</sup>			RA Scenario #2 <sup>2</sup>		
	Patients (n=100)	Controls <sup>£</sup> (n=394)	<i>p</i> *	Patients (n=100)	Controls <sup>£</sup> (n=380)	<i>p</i> *	Patients (n=97)	Controls <sup>£</sup> (n=388)	<i>p</i> *	Patients (n=97)	Controls <sup>£</sup> (n=388)	<i>p</i> *
<b>GES</b>	Mean	27.4 (SD=19.5)	0.001	27.4 (SD=19.5)	21.9 (SD=21.2)	0.001	28.4 (SD=17.3)	19.7 (SD=19.2)	4.026*10 <sup>-7</sup>	28.4 (SD=17.3)	19.9 (SD=17.5)	4.626*10 <sup>-7</sup>
	Median	23.0 (IQR=29.0)		23.0 (IQR=29.0)	17.0 (IQR=19.0)		26.0 (IQR=25.0)	15.0 (IQR=19.0)		26.0 (IQR=25.0)	15.5 (IQR=17.5)	
<b>OES</b>	Mean	13.8 (SD=15.2)	2.068.10 <sup>-10</sup>	13.8 (SD=15.2)	6.1 (SD=13.2)	1.186*10 <sup>-11</sup>	13.1 (SD=12.8)	5.1 (SD=11.1)	<2.2*10 <sup>-16</sup>	13.1 (SD=12.8)	5.1 (SD=10.6)	<2.2*10 <sup>-16</sup>
	Median	9.5 (IQR=20.0)		9.5 (20.0)	0.0 (IQR=6.0)		10.0 (15.0)	0.0 (IQR=5.0)		10.0 (IQR=15.0)		
<b>NOES</b>	Mean	13.7 (SD=9.7)	0.60	13.7 (SD=9.7)	15.8 (SD=12.3)	0.27	15.3 (SD=9.1)	14.7 (SD=12.0)	0.17	15.3 (SD=9.1)	14.8 (SD=11.2)	0.23
	Median	12.0 (IQR=16.5)		12.0 (IQR=16.5)	13.0 (IQR=14.0)		15.0 (IQR=13.0)	12.0 (IQR=17.0)		15.0 (IQR=13.0)		

<sup>£</sup>ELIPSSilice2 respondents are used as controls, matched to SSc and RA patients respectively on sex, age, and tobacco use (number of pack-years).

<sup>1</sup> Scenario #1 : controls were selected among people declaring “not having the disease the matched comparison is made with”.

<sup>2</sup> Scenario #2 : controls were selected among people “declaring having (or having had) none of the chronic conditions (i.e. neither the disease the matched comparison is made with, nor any other chronic conditions evaluated in the questionnaire)”.

\* Wilcoxon test, level of significance  $p < 0.05$

GES: Global exposure score; OES: Occupational exposure score; NOES: Non-occupational exposure score; GES=OES+NOES

567

**Table 2: compared female and male patients' exposure scores from DELCQ in SSc and RA**

Exposure scores	SSc (n=100)			RA (n=97)		
	Women (n=74)	Men (n=26)	<i>p</i> *	Women (n=77)	Men (n=20)	<i>p</i> *
<b>GES</b>	Mean	20.7 (SD=14.5)	1.27*10 <sup>-7</sup>	25.3 (SD=15.0)	40.1 (SD=20.7)	0.002
	Median	17.5 (IQR=20.0)		47.0 (IQR=23.0)	25.0 (IQR=21.0)	
<b>OES</b>	Mean	8.0 (SD=8.5)	3.37*10 <sup>-9</sup>	9.6 (SD=9.0)	26.5 (SD=16.2)	4.11*10 <sup>-6</sup>
	Median	6.0 (IQR=13.0)		26.0 (IQR=22.0)	7.0 (IQR=11.0)	
<b>NOES</b>	Mean	12.7 (SD=9.7)	0.08	15.7 (SD=8.9)	13.5 (SD=9.9)	0.31
	Median	11 (IQR=14.0)		15.5 (IQR=17.0)	15.0 (IQR=12.0)	

\* Wilcoxon test, level of significance  $p < 0.05$

GES: Global exposure score; OES: Occupational exposure score; NOES: Non-occupational exposure ; GES=OES+NOES

568

569

570

571

572

573  
574

**Table 3: Dust exposure scores from DELCQ in the general population (ELIPSSilice1 & 2, N= 2 911) according to the sex of the respondents**

	<b>Female respondents (N=1 519)</b>	<b>Male respondents (N= 1384)</b>
<b>GES</b>		
Mean	13.2 (SD=14.0)	23.2 (SD=24.6)
Median	9.0 (IQR=15.0)	15.0 (IQR=27.0)
<b>OES</b>		
Mean	3.4 (SD=7.2)	11.7 (SD=18.0)
Median	0.0 (IQR=4.0)	4.0 (IQR=16.0)
<b>NOES</b>		
Mean	9.8 (SD=9.4)	11.5 (SD=10.6)
Median	7.0 (IQR=11.0)	9.0 (IQR=15.0)

575  
576  
577

We do not know the sex of 8 respondents: 1 519+1 384=2 903 among 2 911 ELIPSSilice1 & 1 respondents.

**Table 4: Compared dust exposure scores from DELCQ between diagnosed (RA, SSc) patients and controls randomly sampled in ELIPSSilice2 and stratified by sex**

Exposure Scores	SSc Women (n=74)			SSc Men (n=26)			RA Women (n=77)			RA Men (n=20)		
	Patients (n=74)	Controls <sup>‡</sup> Scenario <sup>#1</sup> (n=290)	<i>p</i> <sup>*</sup>	Patients (n=26)	Controls <sup>‡</sup> Scenario <sup>#1</sup> (n=104)	<i>p</i> <sup>*</sup>	Patients (n=77)	Controls <sup>‡</sup> Scenario <sup>#1</sup> (n=308)	<i>p</i> <sup>*</sup>	Patients (n=20)	Controls <sup>‡</sup> Scenario <sup>#1</sup> (n=80)	<i>p</i> <sup>*</sup>
<b>GES</b>	Mean	20.7 (SD=14.5)	0.24	46.5 (SD=19.7)	27.6 (SD=27.5)	3.79*10 <sup>-5</sup>	25.3 (SD=15.0)	18.2 (SD=16.8)	6.55*10 <sup>-6</sup>	40.1 (SD=20.7)	25.7 (SD=25.6)	0.00521
	Median	17.5 (IQR=20.0)		16.0 (IQR=17.0)	47.0 (IQR=23.0)		19.5 (IQR=34.0)	25.0 (IQR=21.0)		14.0 (IQR=18.5)	42.5 (IQR=28.0)	
<b>OES</b>	Mean	8.0 (SD=8.5)	8.65*10 <sup>-7</sup>	30.0 (SD=18.3)	13.4 (SD=20.5)	1.36*10 <sup>-6</sup>	9.6 (SD=9.0)	3.7 (SD=7.5)	8.28*10 <sup>-14</sup>	26.5 (SD=16.2)	10.4 (SD=18.6)	4.445*10 <sup>-6</sup>
	Median	6.0 (IQR=13.0)		0.0 (IQR=5.0)	26.0 (IQR=22.0)		4.5 (IQR=18.5)	7.0 (IQR=1.0)		0.0 (IQR=5.0)	23.5 (IQR=16.5)	
<b>NOES</b>	Mean	12.7 (SD=9.7)	0.09	16.4 (SD=9.5)	14.2 (SD=13.4)	0.1	15.7 (SD=8.9)	14.5 (SD=12.1)	0.045	13.5 (SD=9.9)	15.4 (SD=11.8)	0.66
	Median	11 (IQR=14.0)		13.0 (IQR=15.0)	15.5 (IQR=17.0)		11.0 (IQR=19.5)	15.0 (IQR=12.0)		12.0 (IQR=16.0)	12.0 (IQR=15.5)	

<sup>‡</sup>ELIPSSilice2 respondents are used as controls, matched to SS and RA patients respectively on sex, age, and tobacco use (number of pack-years).

<sup>#1</sup> Scenario #1: controls were selected among people “declaring not having the disease the matched comparison is made with ».

\* Wilcoxon test, level of significance  $p < 0.05$

GES: Global exposure score; OES: Occupational exposure score; NOES: Non-occupational exposure score; GES=OES+NOES